Topiramate
Product Images NDC 45865-459

4 FDA label images from Medsource Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 45865-459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (459)

Pdp (459)
Topiramate Tablets 50 mg label by Medsource Pharmaceuticals, generic for Topamax. The label states the tablet color as light orange and round, with film coating. It includes warnings about dizziness or drowsiness and advises avoiding alcohol. The label directs users to take a specified number of tablets daily.*
FDA Label Image

Topi (6491d395 Ef69 4db7 Abe1 87f061db14d8 01)

Topi (6491d395 Ef69 4db7 Abe1 87f061db14d8 01)
Chemical structure of topiramate, showing its molecular arrangement including oxygen atoms, methyl groups, and a sulfamate group attached to a sugar-like ring system.*
FDA Label Image

Topi (6491d395 Ef69 4db7 Abe1 87f061db14d8 02)

Topi (6491d395 Ef69 4db7 Abe1 87f061db14d8 02)
A line graph showing cumulative rates for time to event on the y-axis versus time (up to 450 units) on the x-axis. Two lines, solid and dotted, represent different groups or conditions, with the solid line showing higher cumulative rates. A p-value of 0.0002 is displayed, indicating statistical comparison between the two lines.*
FDA Label Image

Figure 2: Reduction In 4-week Migraine Headache Frequency (studies 10 And 11 For Adults And Adolescents) (6491d395 Ef69 4db7 Abe1 87f061db14d8 03)

Figure 2: Reduction In 4-week Migraine Headache Frequency	(studies 10 And 11 For Adults And Adolescents) (6491d395 Ef69 4db7 Abe1 87f061db14d8 03)
A bar graph showing change from baseline to double-blind phase in average weekly migraine period rate with standard error bars. It compares placebo and three dosage groups of Topamax (50 mg/day, 100 mg/day, 200 mg/day) across two studies, Study 10 and Study 11. The graph includes statistical significance markers for the Topamax 100 mg/day and 200 mg/day groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.